Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Cytek Biosciences, Inc. (CTKB : NSDQ)
 
 • Company Description   
Cytek Biosciences Inc provides cell analysis solutions. The company developed high-resolution, high-content and high-sensitivity cell analysis technology called Full Spectrum Profiling. Cytek Biosciences Inc is based in FREMONT, Calif.

Number of Employees: 648

 
 • Price / Volume Information   
Yesterday's Closing Price: $4.06 Daily Weekly Monthly
20 Day Moving Average: 835,315 shares
Shares Outstanding: 127.22 (millions)
Market Capitalization: $516.53 (millions)
Beta: 1.31
52 Week High: $7.63
52 Week Low: $2.37
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 3.57% 2.47%
12 Week 20.48% 14.84%
Year To Date -37.44% -44.85%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
47215 Lakeview Blvd.
-
Fremont,CA 94538
USA
ph: 877-922-9835
fax: -
investors@cytekbio.com https://cytekbio.com
 
 • General Corporate Information   
Officers
Wenbin Jiang - President; Chief Executive Officer and Director
William McCombe - Chief Financial Officer
Ming Yan - Chief Technology Officer and Director
Jack Ball - Director
Don Hardison - Director

Peer Information
Cytek Biosciences, Inc. (CORR.)
Cytek Biosciences, Inc. (RSPI)
Cytek Biosciences, Inc. (CGXP)
Cytek Biosciences, Inc. (BGEN)
Cytek Biosciences, Inc. (GTBP)
Cytek Biosciences, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 23285D109
SIC: 3826
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 06/01/25
Next Expected EPS Date: 11/04/25
Share - Related Items
Shares Outstanding: 127.22
Most Recent Split Date: (:1)
Beta: 1.31
Market Capitalization: $516.53 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.03 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.19 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 11/04/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.36
Price/Cash Flow: 117.00
Price / Sales: 2.63
EPS Growth
vs. Year Ago Period: 50.00%
vs. Previous Quarter: 55.56%
Sales Growth
vs. Year Ago Period: -2.18%
vs. Previous Quarter: 10.00%
ROE
09/30/25 - -
06/30/25 - -1.66
03/31/25 - -2.90
ROA
09/30/25 - -
06/30/25 - -1.30
03/31/25 - -2.30
Current Ratio
09/30/25 - -
06/30/25 - 5.22
03/31/25 - 5.62
Quick Ratio
09/30/25 - -
06/30/25 - 4.55
03/31/25 - 4.95
Operating Margin
09/30/25 - -
06/30/25 - -3.27
03/31/25 - -5.71
Net Margin
09/30/25 - -
06/30/25 - -3.27
03/31/25 - -5.71
Pre-Tax Margin
09/30/25 - -
06/30/25 - -3.86
03/31/25 - -4.05
Book Value
09/30/25 - -
06/30/25 - 2.98
03/31/25 - 2.98
Inventory Turnover
09/30/25 - -
06/30/25 - 1.93
03/31/25 - 1.91
Debt-to-Equity
09/30/25 - -
06/30/25 - 0.00
03/31/25 - 0.00
Debt-to-Capital
09/30/25 - -
06/30/25 - 0.21
03/31/25 - 0.24
 

Powered by Zacks Investment Research ©